Site icon pharmaceutical daily

Bispecific CD3 Molecules in Oncology Analytical Handbook 2020: 67 Companies Plus Partners who are Developing 148 Drugs Where 127 are in Active Development – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Bispecific CD3 Molecules in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.

Bispecific CD3 Molecules in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of immune-oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your bispecific CD3 drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

There is a considerable and robust commercial drug pipeline of T-cell redirecting therapies by bispecific compounds that targets various tumor antigens expressed by malignant cells, and CD3 expressed by the T-cell. Upon binding to both targets, these compounds redirect T-cell cytotoxicity toward the malignant cells and effectively eradicate them.

Bispecific CD3 Molecules in Oncology: Analytical Tool achieves this by continuously scanning development in bispecific CD3 and reporting:

Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

(Read more…)

Your Bispecific CD3 Molecules in Oncology: Analytical Tool covers more than 67 companies plus partners who are today developing 148 bispecific CD3 drugs where of 127 are in active development in cancer across 63 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Your key to access development at the world-leading cancer meetings

The Bispecific CD3 Molecules in Oncology: Analytical Tool is continuously updated according to twelve of the world’s most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia)). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The Bispecific CD3 Molecules in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc.

For more information about this report visit https://www.researchandmarkets.com/r/2jcu8n

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version